Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Trade private companies / Buy and sell American Gene Technologies International stock
American Gene Technologies International

American Gene Technologies International stock

Highest bid
$XXXX
x/xx/xx
Lowest ask
$XXXX
x/xx/xx
Last matched price
$XXXX
x/xx/xx
$--
Register to buy and sell private company shares
For more details on private stock price information, financing and valuation for American Gene Technologies International, register or log in.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

American Gene Technologies International stock price

Trade metrics

Market activity 2
Limited
Active bids
XX
Active asks
XX
Highest bid price
$ XXX.XX
Lowest ask price
$ XXX.XX
Total bids
$XXX
Total asks
$XXX
Last matched price
$ XXX.XX
xx/xx/xxxx
Last matched valuation
$ XXX.XX
xx/xx/xxxx

Price history chart

7D
1M
3M
1Y
All
Forge Price
$--
Not yet available
Forge Price valuation
$--

Actively traded Healthcare companies

Active market

The image displayed is not current and any securities shown are for illustrative purposes only.

Forge exclusive fund offerings

Fund offerings
The image displayed is not current and any securities shown are for illustrative purposes only.
Forge exclusive fund offerings
Access high-growth companies at a fixed price—for a limited time
Invest in trending companies with lower minimums
Simplify private investing through a Forge-managed single company fund

American Gene Technologies International stock FAQs

To buy and sell American Gene Technologies International stock

Can you buy American Gene Technologies International stock?

As American Gene Technologies International is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like American Gene Technologies International, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy American Gene Technologies International stock?

To invest in a private company like American Gene Technologies International through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell American Gene Technologies International stock?

Yes, you may sell the American Gene Technologies International stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell American Gene Technologies International stock?

If you hold private company shares of American Gene Technologies International – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your American Gene Technologies International on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about American Gene Technologies International stock

Is American Gene Technologies International a public company?

No, American Gene Technologies International is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is American Gene Technologies International’s stock price?

American Gene Technologies International is a privately held company and therefore does not have a public stock price. However, you may access American Gene Technologies International private market stock price with Forge Data.

What is American Gene Technologies International’s stock ticker symbol?

American Gene Technologies International does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

American Gene Technologies International funding rounds and valuation

Total funding $72.88MM

Funding history chart

Funding round details

Funding Date Share Class Amount Raised Price Per Share Post-Money Valuation 3 Key Investors
12/03/2021 Series F-1 $18MM $12.00 $712.6MM Undisclosed Investors
Price Per Share
$12.00
Shares Outstanding
1,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Undisclosed Investors
04/15/2021 Series E-1 $32.5MM $5.00 $289.42MM Gaingels
Price Per Share
$5.00
Shares Outstanding
6,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Gaingels
02/20/2018 Series D-1 $15.03MM $3.00 $142.47MM Alumni Ventures Group, National Institutes Of Health
Price Per Share
$3.00
Shares Outstanding
5,010,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Alumni Ventures Group, National Institutes Of Health
10/30/2015 Series C-1 $4.35MM $1.50 $55.42MM Undisclosed Investors
Price Per Share
$1.50
Shares Outstanding
2,900,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Undisclosed Investors
09/24/2014 Series B-1 $2MM $0.48 $15.21MM Undisclosed Investors
Price Per Share
$0.48
Shares Outstanding
4,166,666
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Undisclosed Investors
09/03/2013 Series A-1 $1,000,000.00 $0.46 $4MM Undisclosed Investors
Price Per Share
$0.46
Shares Outstanding
2,170,610
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
Undisclosed Investors

Company details

American Gene Technologies ("AGT") is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, infectious disease, immune-oncology, and monogenic disorders.
Founded
2007
Headquarters
Rockville, MD, United States
Leadership
David Pauza Ph.D
Chief Science Officer
Norman Rogers
Executive, Business Development
Jeffrey Galvin
Co-Founder, Chief Executive Officer & Board Member
Neil Lyons
Chief Financial Officer & Executive Vice President
Board
Julia Brown
Qi Tang
Jeffrey Galvin
Aaron Galvin
Tommy Thompson JD

American Gene Technologies International news and media highlights

AGT Spins Out Addimmune, Focusing on Functional HIV Cure

American Gene Technologies (AGT) is spinning out a new company, Addimmune, to focus on developing a cure for HIV. Addimmune will continue AGT's work on AGT103-T, a gene and cell therapy that completed Phase I trials with positive safety results. The therapy is a single-dose treatment that delivers gene-therapy modified, HIV-specific CD4 T cells to people with HIV, with the aim of restoring natural immune control of the virus.

American Gene Technologies thinks spin spin spin is how you win, as HIV unit heads to SPAC

American Gene Technologies (AGT) has signed a blank-check deal to spin off its HIV-focused subsidiary, Addimmune, to special purpose acquisition company 10X Capital Venture Acquisition Corp. III. The deal, which sees all non-HIV assets spun out into a separate entity retaining the AGT name, is expected to close in Q1 2024. The agreement represents a pre-money enterprise value of $500 million for Addimmune and offers $300 million tied to milestones.

American Gene Technologies spinout Addimmune to go public through SPAC merger

The article discusses grocery delivery start-up, Instacart's valuation reaching $39 billion following its latest funding round of $265 million. This valuation is triple its previous one in 2020, indicating a surge in demand for its service amid the pandemic. The firm plans to use the funds for expanding its business.

Rockville company working on HIV cure will go public

American Gene Technologies International plans to make its Addimmune division a publicly traded company via a special purpose acquisition company (SPAC). Addimmune is developing a gene and cell therapy for HIV, and the SPAC spinoff could raise $500 million to fund larger clinical studies. The public offering is expected to be completed in early 2024.
Browse More Insights

Other companies like American Gene Technologies International in the Biotech & Pharma sector

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Price Share Class Post-Money Valuation 3 Price Per Share Amount Raised
Altos LabsAltos Labs--$xx.xxSeries C$6.33B$25.02$1.5B
ApnimedApnimed--$xx.xxSeries D$394.07MM$9.65$16.5MM
BillionToOneBillionToOne--$xx.xxSeries D$1.25B$28.02$130.47MM
Colossal BiosciencesColossal Biosciences--$xx.xxSeries C$10.2B$24.89$200MM
EgenesisEgenesis--$xx.xxSeries D$332.59MM$0.20$90.96MM
Formation BioFormation Bio--$xx.xxSeries D$1.48B$8.18$372MM
InsitroInsitro--$xx.xxSeries C$2.57B$18.29$400MM
Isomorphic LabsIsomorphic Labs--$xx.xx--------
Precision NeurosciencePrecision Neuroscience--$xx.xxSeries C$542.69MM$5.70$102MM
SetPoint MedicalSetPoint Medical--$xx.xxSeries D$471.62MM$1.51$115MM

Forge is your trusted partner to buy and sell American Gene Technologies International stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Most active companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.